Physician profile
Maxwell White
NPI 1043877137
$3,408.88
in general payments reported to CMS, 2019-2025
29 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $28.28 · 2021: $284 · 2022: $462 · 2023: $1,012 · 2024: $947 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $647.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $375.53 | 2020-2024 | |
| Abbvie INC. | $334.07 | 2022-2025 | Synthroid, Ubrelvy, Vraylar |
| Lilly USA, LLC | $259.99 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Azurity Pharmaceuticals, INC. | $250.65 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Idorsia Pharmaceuticals US INC | $177.16 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $163.99 | 2022-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $152.54 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 | |
| Astellas Pharma US INC | $116.01 | 2022-2023 | |
| Amgen INC. | $111.63 | 2021-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $88.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $87.21 | 2019 | |
| Exact Sciences Corporation | $84.88 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.90 | 2022-2023 | Tradjenta, Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $43.17 | 2023 | Loreev Xr, Sertraline Hcl |
| Biohaven Pharmaceutical Holding Company LTD. | $41.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.35 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $35.22 | 2021-2022 | |
| Bausch Health US, LLC | $34.70 | 2022-2023 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $31.18 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $30.57 | 2023 | Trintellix |
| Ucb, INC. | $25.43 | 2022 | |
| Sanofi Pasteur INC. | $23.99 | 2023 | |
| Lundbeck LLC | $17.38 | 2024 | Rexulti |
| Dexcom, INC. | $16.04 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $15.54 | 2024 | Nexletol |
| Currax Pharmaceuticals LLC | $13.73 | 2023 | Contrave |
| Amarin Pharma, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.